Medication info
Telmisartan/Amlodipine/Atorvastatin Tablet 40/5/5 mg

Telmisartan/Amlodipine/Atorvastatin Tablet 40/5/5 mg

Prescription medicationTabletOral
Ingredient · strength
Telmisartan›40mg / 1 tabletAmlodipine Besylate›6.935mg / 1 tabletRosuvastatin Calcium Micronized›5.2mg / 1 tablet
Manufacturer / importer
Jeil Pharmaceutical Co., Ltd.
Appearance
A round bilayer tablet consisting of a white layer and a light blue layer.
Packaging
30 tablets/box [10 tablets/PTP x 3], 30 tablets/bottle
Approval status
Active

MFDS item code 202302798 · Approved 2023.09.21 · Insurance code 645406420

Summary

Main use
Treatment of hypertension and dyslipidemia, and inhibition of atherosclerosis progression and cardiovascular disease risk
Who takes it
Adults
Adult dose
Take 1 tablet once daily with water, regardless of meals. If possible, it is recommended to take it at the same time each day (e.g., in the morning). This medicine is for adults only. The dose should be individualized for each patient based on the efficacy and tolerability of the telmisartan/amlodipine combination and rosuvastatin. For patients taking a telmisartan/amlodipine combination and rosuvastatin as separate products, they may switch to this medicine (a combination product containing the same amount of each active ingredient) for convenience. ○ Telmisartan/amlodipine combination Before administering the telmisartan/amlodipine combination, it is recommended to adjust the dose using the individual components (amlodipine or telmisartan). However, if blood pressure is not controlled with the individual components, a direct switch to the telmisartan/amlodipine combination may be considered as follows. - 40/5 mg: For patients whose blood pressure is not adequately controlled with amlodipine 5 mg or telmisartan 40 mg. - 80/5 mg: For patients whose blood pressure is not adequately controlled with amlodipine 5 mg or this medicine 40/5 mg. - 40/10 mg: For patients whose blood pressure is not adequately controlled with amlodipine 10 mg. - 80/10 mg: For patients whose blood pressure is not adequately controlled with amlodipine 10 mg or this medicine 40/10 mg. ◦ Patients with renal impairment: No dose adjustment is necessary in patients with mild or moderate renal impairment. In patients with severe renal impairment, however, it is recommended to initiate treatment at a low dose and gradually increase the dose. Periodic monitoring of serum potassium and creatinine levels is also recommended. ◦ Patients with hepatic impairment: The daily dose of telmisartan should not exceed 40 mg in patients with mild or moderate hepatic impairment. ◦ Elderly patients: In patients aged 75 years or older, amlodipine clearance is reduced; therefore, initiate treatment at a low dose and gradually increase the dose. ○ Rosuvastatin 1. Primary hypercholesterolemia (type IIa, including heterozygous familial hypercholesterolemia), mixed dyslipidemia (type IIb), primary dysbetalipoproteinemia (type III), and homozygous familial hypercholesterolemia Patients should follow a standard cholesterol-lowering diet before and during treatment with rosuvastatin, and continue it throughout the treatment period. Rosuvastatin may be taken at any time of day, regardless of meals. The initial dose is 5 mg once daily. If a greater reduction in LDL cholesterol is required, the dose may be adjusted to the maintenance dose. The maintenance dose is 10 mg once daily, which is adequate for most patients. The maintenance dose should be adjusted as appropriate at intervals of 4 weeks or longer according to LDL cholesterol levels, treatment goals, and patient response; the dose may be increased up to a maximum of 20 mg once daily. 2. Elderly patients: No dose adjustment is necessary. 3. Patients with renal impairment: No dose adjustment is necessary in patients with mild or moderate renal impairment. Do not administer to patients with severe renal impairment. Particular caution should be exercised when administering rosuvastatin 20 mg to patients with moderate renal impairment. 4. Patients with hepatic impairment: No increase in systemic exposure to rosuvastatin was observed in patients with a Child-Pugh score of 7 or less, but an increase was observed in patients with a Child-Pugh score of 8 or 9. Renal function testing should be considered in these patients. There is no experience with administration in patients with a Child-Pugh score greater than 9. Do not administer rosuvastatin to patients with active liver disease. 5. Race: Because systemic exposure to rosuvastatin is increased in Asian patients, the recommended initial dose is 5 mg. The 40 mg dose is contraindicated. 6. Patients predisposed to myopathy: The recommended initial dose for patients predisposed to myopathy is 5 mg. The 40 mg dose of rosuvastatin is contraindicated in some of these patients. In a drug interaction study of the active ingredients of this medicine, telmisartan/amlodipine 80/10 mg and rosuvastatin 20 mg, the Cmax of rosuvastatin increased approximately 2.1-fold and the AUC approximately 1.2-fold in the presence of telmisartan/amlodipine. Therefore, when administering this medicine, assess the potential risk resulting from the increase in rosuvastatin Cmax and monitor patients closely.

Ingredients

Manufacturer
Jeil Pharmaceutical Co., Ltd.

Efficacy & effects

Treatment of hypertension and dyslipidemia, and inhibition of atherosclerosis progression and cardiovascular disease risk

  • Essential hypertension
  • primary hypercholesterolemia
  • heterozygous familial hypercholesterolemia
  • mixed hyperlipidemia
  • homozygous familial hypercholesterolemia
  • hypercholesterolemia
  • primary dysbetalipoproteinemia
  • increased high-sensitivity C-reactive protein
  • hypertension
  • low HDL cholesterol levels
  • smoking
  • and a family history of early coronary artery disease.
View approved original text

This medication is used for patients with essential hypertension whose blood pressure is not adequately controlled with telmisartan and amlodipine combination therapy. Additionally, atorvastatin is helpful for the treatment of hypercholesterolemia that is not controlled by diet and exercise, mixed hyperlipidemia, and familial hypercholesterolemia. Atorvastatin lowers total cholesterol and LDL cholesterol levels in patients at high risk for cardiovascular disease, slowing the progression of atherosclerosis. This medication is also effective in reducing the risk of cardiovascular disease, preventing strokes and myocardial infarctions, and decreasing the recurrence risk after arterial revascularization. Therefore, it is used for patients who need improvements in blood pressure and blood lipid levels.

How to take

Adult dose

Take 1 tablet once daily with water, regardless of meals. If possible, it is recommended to take it at the same time each day (e.g., in the morning). This medicine is for adults only. The dose should be individualized for each patient based on the efficacy and tolerability of the telmisartan/amlodipine combination and rosuvastatin. For patients taking a telmisartan/amlodipine combination and rosuvastatin as separate products, they may switch to this medicine (a combination product containing the same amount of each active ingredient) for convenience. ○ Telmisartan/amlodipine combination Before administering the telmisartan/amlodipine combination, it is recommended to adjust the dose using the individual components (amlodipine or telmisartan). However, if blood pressure is not controlled with the individual components, a direct switch to the telmisartan/amlodipine combination may be considered as follows. - 40/5 mg: For patients whose blood pressure is not adequately controlled with amlodipine 5 mg or telmisartan 40 mg. - 80/5 mg: For patients whose blood pressure is not adequately controlled with amlodipine 5 mg or this medicine 40/5 mg. - 40/10 mg: For patients whose blood pressure is not adequately controlled with amlodipine 10 mg. - 80/10 mg: For patients whose blood pressure is not adequately controlled with amlodipine 10 mg or this medicine 40/10 mg. ◦ Patients with renal impairment: No dose adjustment is necessary in patients with mild or moderate renal impairment. In patients with severe renal impairment, however, it is recommended to initiate treatment at a low dose and gradually increase the dose. Periodic monitoring of serum potassium and creatinine levels is also recommended. ◦ Patients with hepatic impairment: The daily dose of telmisartan should not exceed 40 mg in patients with mild or moderate hepatic impairment. ◦ Elderly patients: In patients aged 75 years or older, amlodipine clearance is reduced; therefore, initiate treatment at a low dose and gradually increase the dose. ○ Rosuvastatin 1. Primary hypercholesterolemia (type IIa, including heterozygous familial hypercholesterolemia), mixed dyslipidemia (type IIb), primary dysbetalipoproteinemia (type III), and homozygous familial hypercholesterolemia Patients should follow a standard cholesterol-lowering diet before and during treatment with rosuvastatin, and continue it throughout the treatment period. Rosuvastatin may be taken at any time of day, regardless of meals. The initial dose is 5 mg once daily. If a greater reduction in LDL cholesterol is required, the dose may be adjusted to the maintenance dose. The maintenance dose is 10 mg once daily, which is adequate for most patients. The maintenance dose should be adjusted as appropriate at intervals of 4 weeks or longer according to LDL cholesterol levels, treatment goals, and patient response; the dose may be increased up to a maximum of 20 mg once daily. 2. Elderly patients: No dose adjustment is necessary. 3. Patients with renal impairment: No dose adjustment is necessary in patients with mild or moderate renal impairment. Do not administer to patients with severe renal impairment. Particular caution should be exercised when administering rosuvastatin 20 mg to patients with moderate renal impairment. 4. Patients with hepatic impairment: No increase in systemic exposure to rosuvastatin was observed in patients with a Child-Pugh score of 7 or less, but an increase was observed in patients with a Child-Pugh score of 8 or 9. Renal function testing should be considered in these patients. There is no experience with administration in patients with a Child-Pugh score greater than 9. Do not administer rosuvastatin to patients with active liver disease. 5. Race: Because systemic exposure to rosuvastatin is increased in Asian patients, the recommended initial dose is 5 mg. The 40 mg dose is contraindicated. 6. Patients predisposed to myopathy: The recommended initial dose for patients predisposed to myopathy is 5 mg. The 40 mg dose of rosuvastatin is contraindicated in some of these patients. In a drug interaction study of the active ingredients of this medicine, telmisartan/amlodipine 80/10 mg and rosuvastatin 20 mg, the Cmax of rosuvastatin increased approximately 2.1-fold and the AUC approximately 1.2-fold in the presence of telmisartan/amlodipine. Therefore, when administering this medicine, assess the potential risk resulting from the increase in rosuvastatin Cmax and monitor patients closely.

Precautions

This medication should not be used in pregnant women and must be stopped immediately if pregnancy is confirmed, as it can cause serious harm to the fetus and newborn. Patients with allergies to the active ingredients or components of this medication, specific hereditary diseases, or severe liver or kidney diseases should avoid using it. Additionally, patients with certain muscle diseases or a history of muscle-related side effects in the past should also avoid its use. Some patients, such as those with hypertension, liver function impairment, the elderly, and those with hyperkalemia, require special caution when using this medication. If muscle pain or weakness occurs, it is crucial to consult a doctor immediately. This medication lowers blood pressure, so caution is necessary for patients with hypotension or cardiovascular diseases. To prevent muscle-related side effects, it is recommended to regularly check muscle enzyme levels before starting and during treatment. As this medication can affect liver function, periodic monitoring of liver enzyme levels is also required. When taken together with other medications, drug interactions may occur, so it is essential to inform the doctor or pharmacist of any other medications being used. Particularly, concomitant use with certain antibiotics, antifungals, immunosuppressants, and some antivirals may increase the risk of muscle side effects. Women who may become pregnant should use appropriate contraception while taking this medication, and it is advisable for breastfeeding mothers to avoid this medication. Safety and effectiveness have not been sufficiently confirmed for children and adolescents under 18 years, so its use is not recommended. In case of overdose, symptoms such as hypotension, dizziness, and heart rhythm abnormalities may occur, requiring immediate medical assistance. This medication should be kept out of reach of children and should not be transferred to another container. During use, dizziness or drowsiness may occur while driving or operating dangerous machinery, so caution is advised.

Side effects

Peripheral edema, dyspepsia, frequent bowel movements, diabetes mellitus, dizziness, dry vesicular sounds, urticaria, unstable angina, onychomycosis, lumbar spinal stenosis, ear discharge, vertigo, chronic gastritis, various gastrointestinal disorders, hiatal hernia, dysuria, rhinitis, oropharyngeal discomfort, pulmonary disease, unspecified bowel disease, benign gastrointestinal neoplasm, hemorrhoids, skeletal pain, osteoporosis, sensory loss, movement disorders, atherosclerosis, frequent urination, tinnitus, hearing loss, halitosis, fatty liver, upper respiratory tract infection, lower back pain, sinusitis, diarrhea, pharyngitis, influenza-like illness, myalgia, urinary tract infection, abdominal pain, headache, dizziness, pain, fatigue, cough, hypertension, chest pain, nausea, vascular edema, fever, leg pain, lethargy, palpitations, dependent edema, angina, rapid pulse, leg edema, abnormal ECG, insomnia, drowsiness, migraine, lightheadedness, paresthesia, involuntary muscle contractions, erectile dysfunction, increased sweating, flushing, allergy, vasculitis, peripheral neuropathy, tremors, dysphagia, pancreatitis, gingival hyperplasia, asthenia, burning sensation, rigidity, weight gain, weight loss, arthralgia, osteoarthritis, muscle cramps, sexual dysfunction, insomnia, neuroexcitation, depression, abnormal dreams, anxiety, depersonalization, dyspnea, epistaxis, polymorphic erythema, rash, erythematous rash, papular rash, diplopia, ocular pain, urinary disorders, nocturia, dry mouth, hyperglycemia, thirst, leukopenia, purpura, thrombocytopenia, vascular edema, headache, dizziness, constipation, nausea, abdominal pain, pancreatitis, pruritus, rash, urticaria, myalgia, myopathy, rhabdomyolysis, asthenia, thrombocytopenia, jaundice, hepatitis, Stevens-Johnson syndrome, eosinophilia with systemic symptoms drug reaction syndrome, lupus-like syndrome, muscle rupture, immune-mediated necrotizing myopathy, hematuria, edema, depression, sleep disorders, interstitial lung disease, sexual dysfunction, gynecomastia, fatal and non-fatal liver failure, memory impairment, forgetfulness, amnesia, memory disorders, confusion, acute kidney injury, anemia, CPK elevation, anaphylactic reaction, tendon pain, thrombocytopenia, increased uric acid, liver dysfunction, liver disease, syncope, generalized pain, muscle cramps, gout, erectile dysfunction, joint pain, fatigue, numbness, paresthesia, chest discomfort, loss of appetite, abdominal distension, abnormal liver function tests, syncope, generalized pain, muscle cramps, gout, erectile dysfunction

Not everyone experiences these, and they can vary from person to person.

Storage

This medication may be sensitive to light, so it is stored in special containers that block light. Additionally, it is kept in sealed containers to avoid contact with air. It is essential to maintain storage at room temperature, between 1°C and 30°C, to ensure the drug's effectiveness is preserved safely.

Appearance and packaging

Appearance

A round bilayer tablet consisting of a white layer and a light blue layer.

Package unit

30 tablets/box [10 tablets/PTP x 3], 30 tablets/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.